Sudeep Pharma Ltd. (SUDEEPPHRM) fundamentals
Sudeep Pharma Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SUDEEPPHRM (ISIN INE0QPI01025). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Sudeep Pharma Ltd. does
Sudeep Pharma Private Limited is an India-based manufacturing pharmaceutical and nutraceutical products company. The Company is engaged in business of manufacturing and selling pharmaceutical and food, nutrition and specialty ingredients and intermediaries, used by pharmaceutical, food and nutrition industries globally. The Company a wide range of products, including mineral salts such as calcium salts, zinc salts, iron salts, potassium salts, magnesium salts, sodium salts, simethicone salts and copper salts. It offers products to a wide range of markets, which includes pharmaceuticals, dietary health, infant nutrition, beverage, dairy products, bakery products, confectionery, and staple food markets. Its subsidiaries include Sudeep Nutrition Private Limited, Sudeep Pharma USA Inc., Sudeep Pharma B.V., and Sudeep Advanced Materials Private Limited.
Valuation and market data
| Last close | ₹1213.50 |
|---|---|
| Market capitalisation | ₹13,644 crore |
| Enterprise value | ₹13,693 crore |
| P/E (TTM) | 78.29 |
| Price to book | 15.19 |
| Price to sales (TTM) | 11.78 |
| Book value per share | ₹79.87 |
| Dividend yield | 12.36% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Nov 28 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹671 crore | ₹228 crore | ₹174 crore | 15.50 |
| Mar 2025 | ₹511 crore | ₹183 crore | ₹139 crore | 12.79 |
| Mar 2024 | ₹465 crore | ₹175 crore | ₹133 crore | 12.28 |
| Mar 2023 | ₹438 crore | ₹86 crore | ₹62 crore | 5.74 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 76.2% |
|---|---|
| Foreign institutions (FII) | 1.8% |
| Mutual funds | 5.5% |
| Other domestic institutions | 10.2% |
| Retail and others | 6.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.